Dabigatran etexilate PK with or without pantoprazole in healthy elderly

Phase 1, open-label trial of dabigatran etexilate oral solution in thromboembolism, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration time curve during a dosing interval at steady state at Day 7, Maximum measured concentration of the analyte in plasma at steady state at Day 7 and 6 more. Started Nov 2002; status: completed.